Evidence map›Paper›PMID 33567615›Full record

ArticleMolecules (Basel, Switzerland)2021

Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A

Bassam M Ayoub, Haidy E Michel, Shereen Mowaka, Moataz S Hendy, Mariam M Tadros

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Dapagliflozin Ameliorate Type-2 Diabetes Associated Neuropathy via Regulation of IGF-1R Signaling.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bassam M AyoubPharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.ORCID 0000-0002-3265-1567
Haidy E MichelPharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Street, Abassia, Cairo 11566, Egypt.ORCID 0000-0003-4174-5749
Shereen MowakaPharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Moataz S HendyPharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Mariam M TadrosPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Street, Abassia, Cairo 11566, Egypt.
British University in Egypt · EGAin Shams University · EG

Funding

Science and Technology Development Fund 32340
6 · The paper itself

Abstract

The authors in the current work suggested the potential repurposing of omarigliptin (OMR) for neurodegenerative diseases based on three new findings that support the preliminary finding of crossing BBB after a single dose study in the literature. The first finding is the positive results of the docking study with the crystal structures of A

Indexed as

Drug RepositioningMolecular Docking SimulationAcetylcholinesteraseAnimalsBlood-Brain BarrierBrainChromatography, LiquidDose-Response Relationship, DrugGlucagon-Like Peptide 1Heterocyclic Compounds, 2-RingNeuroprotective AgentsProtein ConformationPyransRatsReceptor, Adenosine A2ATandem Mass Spectrometry2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amineAcetylcholinesteraseGlucagon-Like Peptide 1Heterocyclic Compounds, 2-RingNeuroprotective AgentsPyransReceptor, Adenosine A2A28 days multiple dosesA2A adenosine receptoracetylcholine esterase receptordockingGLP-1LC-MS/MSomarigliptinrats’ brain tissuerats’ plasmarepurposing

Identifiers

PMID33567615
PMCPMC7915074
OpenAlexW3126500640

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.